scholarly journals Peritoneal M2 macrophage transplantation as a potential cell therapy for enhancing renal repair in acute kidney injury

2020 ◽  
Vol 24 (6) ◽  
pp. 3314-3327 ◽  
Author(s):  
Ruiwen Mao ◽  
Chengshi Wang ◽  
Fuping Zhang ◽  
Meng Zhao ◽  
Shuyun Liu ◽  
...  
Keyword(s):  
Acute Kidney Injury ◽  
Cell Therapy ◽  
Kidney Injury ◽  
M2 Macrophage ◽  
Renal Repair

scholarly journals Stem cell-based treatment of kidney diseases

2020 ◽  
Vol 245 (10) ◽  
pp. 902-910
Author(s):  
Binbin Pan ◽  
Guoping Fan
Keyword(s):  
Chronic Kidney Disease ◽  
Stem Cells ◽  
Acute Kidney Injury ◽  
Stem Cell ◽  
Kidney Disease ◽  
Cell Therapy ◽  
Kidney Diseases ◽  
Kidney Injury ◽  
Great Promise ◽  
Kidney Organoids

Kidney dysfunction, including chronic kidney disease and acute kidney injury, is a globally prevalent health problem. However, treatment regimens are still lacking, especially for conditions involving kidney fibrosis. Stem cells hold great promise in the treatment of chronic kidney disease and acute kidney injury, but success has been hampered by insufficient incorporation of the stem cells in the injured kidney. Thus, new approaches for the restoration of kidney function after acute or chronic injury have been explored. Recently, kidney organoids have emerged as a useful tool in the treatment of kidney diseases. In this review, we discuss the mechanisms and approaches of cell therapy in acute kidney injury and chronic kidney disease, including diabetic kidney disease and lupus nephritis. We also summarize the potential applications of kidney organoids in the treatment of kidney diseases. Impact statement Stem cells hold great promise in regenerative medicine. Pluripotent stem cells have been differentiated into kidney organoids to understand human kidney development and to dissect renal disease mechanisms. Meanwhile, recent studies have explored the treatment of kidney diseases using a variety of cells, including mesenchymal stem cells and renal derivatives. This mini-review discusses the diverse mechanisms underlying current renal disease treatment via stem cell therapy. We postulate that clinical applications of stem cell therapy for kidney diseases can be readily achieved in the near future.

Pathophysiology of Acute Kidney Injury, Repair, and Regeneration

2014 ◽  
Author(s):  
Ching-Wei Tsai ◽  
Sanjeev Noel ◽  
Hamid Rabb
Keyword(s):  
Acute Kidney Injury ◽  
Kidney Disease ◽  
Critical Role ◽  
Recovery Period ◽  
Kidney Tissue ◽  
Kidney Injury ◽  
Inflammatory Factors ◽  
Phase Cell ◽  
M2 Macrophage ◽  
Renal Stem Cells

Acute kidney injury (AKI), regardless of its aetiology, can elicit persistent or permanent kidney tissue changes that are associated with progression to end-stage renal disease and a greater risk of chronic kidney disease (CKD). In other cases, AKI may result in complete repair and restoration of normal kidney function. The pathophysiological mechanisms of renal injury and repair include vascular, tubular, and inflammatory factors. The initial injury phase is characterized by rarefaction of peritubular vessels and engagement of the immune response via Toll-like receptor binding, activation of macrophages, dendritic cells, natural killer cells, and T and B lymphocytes. During the recovery phase, cell adhesion molecules as well as cytokines and chemokines may be instrumental by directing the migration, differentiation, and proliferation of renal epithelial cells; recent data also suggest a critical role of M2 macrophage and regulatory T cell in the recovery period. Other processes contributing to renal regeneration include renal stem cells and the expression of growth hormones and trophic factors. Subtle deviations in the normal repair process can lead to maladaptive fibrotic kidney disease. Further elucidation of these mechanisms will help discover new therapeutic interventions aimed at limiting the extent of AKI and halting its progression to CKD or ESRD.

PhaseI/II interim analysis of extracorporeal mesenchymal Stromal cell therapy (SBI-101 Therapy) in subjects with acute kidney injury

Cytotherapy ◽  
2019 ◽  
Vol 21 (5) ◽  
pp. e5
Author(s):  
R. Barcia ◽  
A. Allen ◽  
N. Vaninov ◽  
S. Nguyen ◽  
L. Goodale ◽  
...  
Keyword(s):  
Acute Kidney Injury ◽  
Cell Therapy ◽  
Interim Analysis ◽  
Mesenchymal Stromal Cell ◽  
Stromal Cell ◽  
Kidney Injury

scholarly journals Cell Therapy, Advanced Materials, and New Approaches to Acute Kidney Injury

2009 ◽  
Vol 37 (1) ◽  
pp. 137-143
Author(s):  
Alexander S. Yevzlin ◽  
H. David Humes
Keyword(s):  
Acute Kidney Injury ◽  
Cell Therapy ◽  
Kidney Injury ◽  
Advanced Materials ◽  
New Approaches

scholarly journals Rapidly Progressive Acute Kidney Injury Associated with Nivolumab Treatment

2020 ◽  
Vol 13 (1) ◽  
pp. 85-90 ◽  
Author(s):  
Sachi Okawa ◽  
Keiichi Fujiwara ◽  
Atsushi Shimonishi ◽  
Hiroaki Matsuura ◽  
Taichi Ozeki ◽  
...  
Keyword(s):  
Acute Kidney Injury ◽  
T Cells ◽  
Adverse Event ◽  
Clinical Practice ◽  
Serum Creatinine ◽  
Renal Biopsy ◽  
Kidney Injury ◽  
Pulmonary Adenocarcinoma ◽  
M2 Macrophage ◽  
Tubulointerstitial Inflammation

A 63-year-old man with pulmonary adenocarcinoma was treated with nivolumab. High fever developed within several hours after the first administration of nivolumab; subsequently, serum creatinine levels kept increasing daily. We diagnosed acute kidney injury (AKI) as an immune-related adverse event; the patient was initially treated with 50 mg prednisolone, and the dose was then tapered. Renal biopsy pathologically revealed tubulointerstitial inflammation with strong infiltration of only T cells that were CD3+, CD4+, and CD8+. The infiltration of CD163+ M2 macrophage was also observed. AKI within 1 week after the administration of nivolumab seems to be rare; therefore, the present case provides important findings useful in daily clinical practice.

scholarly journals Extracorporeal Stromal Cell Therapy for Subjects With Dialysis-Dependent Acute Kidney Injury

2018 ◽  
Vol 3 (5) ◽  
pp. 1119-1127 ◽  
Author(s):  
Brian L.K. Miller ◽  
Payal Garg ◽  
Ben Bronstein ◽  
Elizabeth LaPointe ◽  
Herb Lin ◽  
...  
Keyword(s):  
Acute Kidney Injury ◽  
Cell Therapy ◽  
Stromal Cell ◽  
Kidney Injury

scholarly journals Extracorporeal mesenchymal stromal cell therapy (SBI-101) in severe COVID-19 complicated by acute kidney injury

Cytotherapy ◽  
2021 ◽  
Vol 23 (5) ◽  
pp. S20
Author(s):  
J. Teixiera ◽  
M.G. Atta ◽  
L. Noureddine ◽  
S. Nguyen ◽  
B. O’Rourke ◽  
...  
Keyword(s):  
Acute Kidney Injury ◽  
Cell Therapy ◽  
Mesenchymal Stromal Cell ◽  
Stromal Cell ◽  
Kidney Injury
Sign in / Sign up

Export Citation Format

Share Document